Transdermal Drug Delivery News

1. Strategic Partnership For Dose Counter Technology Production 7/11/2023

   Kindeva Drug Delivery, a global leader in contract drug delivery development and manufacturing services and technology, and H&T Presspart, a market leader in respiratory drug delivery systems design, development, and manufacturing, are partnering with Chiesi Group, an international research-focused biopharmaceutical and healthcare group, for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. 

2. Nutriband With Kindeva Drug Delivery Select Aversa Fentanyl Abuse Deterrent Formulation For Commercial Scale Manufacturing Process Development 4/4/2023

   Nutriband Inc. with Kindeva Drug Delivery (“Kindeva”) have selected the target AVERSA formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system.

3. Windgap Medical Appoints Aaron Mann As CEO, Michael Samar As CFO 2/13/2023

   Both bring significant industry tenure and experience to their roles, and with Windgap Co-Founder Brent Buchine, will lead the company's continued growth in the field of complex injectable drug delivery solutions.

4. Kindeva And Meridian Combine: Create Leading Drug-Device Combination Product CDMO 12/13/2022

   The combination has created a leading global contract development and manufacturing organization (“CDMO”) focused on drug-device combination products. The combination will operate under the Kindeva name, with Meridian operating as, “Meridian Medical Technologies, a Kindeva Company”.

5. Kindeva Drug Delivery And Meridian Medical Technologies To Combine 11/15/2022

   Kindeva Drug Delivery announced that it will combine with Meridian Medical Technologies. The combination will create a leading global drug-device combination product CDMO. Kindeva and Meridian will continue to operate independently until closing.

6. Nutriband With Kindeva Drug Delivery Demonstrate Enhanced Abuse-Deterrent Characteristics For Aversa™ Fentanyl 10/4/2022

   Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating can be manufactured using standard commercial transdermal manufacturing processes, which is critical to the success of the product development program.

7. West Makes Minority Investment In Dublin-Based Latch Medical, A Developer Of Vaccine And Biologics Delivery Platforms 8/15/2022

   West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced it has made a strategic investment in Latch Medical, a Dublin-based leader in next-generation vaccine and biologics delivery technology that is pioneering a new approach to intradermal delivery.

8. Kindeva Drug Delivery Announces Collaboration With Synopsys 6/15/2022

   Kindeva Drug Delivery (Kindeva) has announced a collaboration with Synopsys, Inc. involving the implementation of Synopsys Simpleware™ automated software solutions to assist in creating a state-of-the-art system for accurately measuring Kindeva’s microstructured transdermal system (MTS) arrays.

9. Kindeva And BOL Pharma Using Low Global Warming Potential (GWP) Propellant In Development Of Inhaled Cannabinoid Products 5/11/2022

   Subject to all required regulatory approvals, the products under development are targeted to treat chronic neuropathic pain. If successful, this early-stage activity could lead to the long-term commercial supply of regulated inhaled cannabinoid products using low GWP propellants, leveraging Kindeva’s commercial manufacturing capabilities and BOL’s accumulated know-how and innovation in the field of medical cannabis.

10. Virpax Pharmaceuticals Selects Kindeva Drug Delivery As Development Partner For Diclofenac pMDI Commercialization 4/27/2022

    Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) and Kindeva Drug Delivery will work together to advance the clinical program of the Virpax-developed Diclofenac topical spray film (Epoladerm™) in the United States.